|
AU2007292993B2
(en)
|
2006-09-07 |
2013-01-24 |
Idorsia Pharmaceuticals Ltd |
Pyridin-4-yl derivatives as immunomodulating agents
|
|
NZ580454A
(en)
|
2007-03-16 |
2011-05-27 |
Actelion Pharmaceuticals Ltd |
Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
|
|
PT2195311E
(pt)
|
2007-08-17 |
2011-05-25 |
Actelion Pharmaceuticals Ltd |
Derivados de piridina como moduladores do receptor s1p1/edg1
|
|
CA2700917A1
(en)
|
2007-11-01 |
2009-05-07 |
Actelion Pharmaceuticals Ltd |
Novel pyrimidine derivatives
|
|
KR20100095593A
(ko)
|
2007-12-10 |
2010-08-31 |
액테리온 파마슈티칼 리미티드 |
Ｓ１ｐ１/ｅｄｇ１의 작동약으로서 티오펜 유도체
|
|
JP5481395B2
(ja)
|
2008-03-07 |
2014-04-23 |
アクテリオン ファーマシューティカルズ リミテッド |
新規なアミノメチルベンゼン誘導体
|
|
AU2009258242B2
(en)
|
2008-05-14 |
2015-07-16 |
The Scripps Research Institute |
Novel modulators of sphingosine phosphate receptors
|
|
HUE043090T2
(hu)
|
2008-06-09 |
2019-08-28 |
Univ Muenchen Ludwig Maximilians |
Gyógyszerek fehérjék aggregálódásának gátlására olyan betegségeknél, amelyek fehérje-aggregálódással és/vagy neurodegeneratív megbetegedésekkel függnek össze
|
|
US20100010053A1
(en)
*
|
2008-06-20 |
2010-01-14 |
Jose Luis Castro Pineiro |
Compounds
|
|
KR20190004843A
(ko)
|
2008-07-23 |
2019-01-14 |
아레나 파마슈티칼스, 인크. |
자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
|
|
JP5726737B2
(ja)
|
2008-08-27 |
2015-06-03 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
自己免疫障害および免疫性障害の治療において有用なｓ１ｐ１受容体のアゴニストとしての置換三環式酸誘導体
|
|
WO2010085582A1
(en)
|
2009-01-23 |
2010-07-29 |
Bristol-Myers Squibb Company |
Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
|
|
WO2010085584A1
(en)
|
2009-01-23 |
2010-07-29 |
Bristol-Myers Squibb Company |
Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
|
|
JP2012515787A
(ja)
|
2009-01-23 |
2012-07-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
自己免疫疾患および炎症性疾患の処置におけるｓ１ｐアゴニストとしての置換オキサジアゾール誘導体
|
|
SI2454255T1
(sl)
|
2009-07-16 |
2014-01-31 |
Actelion Pharmaceuticals Ltd. |
Derivati piridin-4-ila kot agonisti s1p1/edg1
|
|
US8399451B2
(en)
|
2009-08-07 |
2013-03-19 |
Bristol-Myers Squibb Company |
Heterocyclic compounds
|
|
RS61829B1
(sr)
*
|
2009-11-13 |
2021-06-30 |
Receptos Llc |
Selektivni modulatori receptora sfingozin 1 fosfata i metode hiralne sinteze
|
|
RS57070B1
(sr)
*
|
2009-11-13 |
2018-06-29 |
Celgene Int Ii Sarl |
Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza
|
|
AU2015202660B2
(en)
*
|
2009-11-13 |
2016-10-27 |
Receptos Llc |
Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis
|
|
AU2010319982B2
(en)
*
|
2009-11-13 |
2016-02-04 |
Receptos Llc |
Selective heterocyclic sphingosine 1 phosphate receptor modulators
|
|
CN108558740B
(zh)
|
2010-01-27 |
2021-10-19 |
艾尼纳制药公司 |
S1p1受体调节剂及其盐的制备方法
|
|
CA2789480A1
(en)
|
2010-03-03 |
2011-09-09 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
|
|
EP2390252A1
(en)
*
|
2010-05-19 |
2011-11-30 |
Almirall, S.A. |
New pyrazole derivatives
|
|
WO2012040532A1
(en)
*
|
2010-09-24 |
2012-03-29 |
Bristol-Myers Squibb Company |
Substituted oxadiazole compounds and their use as s1p1 agonists
|
|
KR101869120B1
(ko)
|
2011-01-19 |
2018-06-19 |
이도르시아 파마슈티컬스 리미티드 |
2-메톡시-피리딘-4-일 유도체
|
|
US8865754B2
(en)
|
2011-03-03 |
2014-10-21 |
Proteotech Inc. |
Compounds for the treatment of neurodegenerative diseases
|
|
CN102718726A
(zh)
*
|
2011-03-31 |
2012-10-10 |
上海铂力生物科技有限公司 |
作为免疫调节剂的(z)-5-苯亚甲基噻唑啉-4-酮衍生物
|
|
US9481659B2
(en)
|
2011-05-13 |
2016-11-01 |
Celgene International Ii Sàrl |
Selective heterocyclic sphingosine 1 phosphate receptor modulators
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US9199975B2
(en)
|
2011-09-30 |
2015-12-01 |
Asana Biosciences, Llc |
Biaryl imidazole derivatives for regulating CYP17
|
|
WO2013134562A1
(en)
|
2012-03-09 |
2013-09-12 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
CA2894281C
(en)
|
2012-12-20 |
2021-04-20 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
PT2958913T
(pt)
|
2013-02-20 |
2018-12-03 |
Lg Chemical Ltd |
Agonistas de recetores de esfingosina-1-fosfato, métodos para a sua preparação e composições farmacêuticas que os contêm como agente ativo
|
|
MX363545B
(es)
*
|
2013-03-15 |
2019-03-27 |
Idorsia Pharmaceuticals Ltd |
Derivados piridin-4-ilo.
|
|
EP3041826A4
(en)
|
2013-09-06 |
2017-02-15 |
Inception 2, Inc. |
Triazolone compounds and uses thereof
|
|
EP2853532B1
(en)
*
|
2013-09-28 |
2020-12-09 |
Instytut Farmakologii Polskiej Akademii Nauk |
1,2,4-oxadiazole derivatives as allosteric modulators of metabotropic glutamate receptors belonging to group III
|
|
WO2015066515A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Receptos, Inc. |
Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
|
|
AU2015281799B2
(en)
*
|
2014-06-26 |
2019-11-28 |
Central Adelaide Local Health Network Incorporated |
Enzyme interacting agents
|
|
PL3242666T3
(pl)
|
2015-01-06 |
2025-02-17 |
Arena Pharmaceuticals, Inc. |
Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
|
|
AU2016246398A1
(en)
|
2015-04-06 |
2017-10-26 |
Auspex Pharmaceuticals, Inc. |
Deuterium-substituted oxadiazoles
|
|
ES2770348T3
(es)
|
2015-05-20 |
2020-07-01 |
Idorsia Pharmaceuticals Ltd |
Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
|
|
HUE060476T2
(hu)
|
2015-06-22 |
2023-03-28 |
Arena Pharm Inc |
(R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
|
|
ES3022204T3
(en)
|
2016-06-14 |
2025-05-28 |
Receptos Llc |
Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
|
|
WO2018033149A1
(zh)
|
2016-08-19 |
2018-02-22 |
苏州科睿思制药有限公司 |
奥扎莫德的晶型及其制备方法
|
|
CN109640982A
(zh)
|
2016-09-14 |
2019-04-16 |
苏州科睿思制药有限公司 |
奥扎莫德盐酸盐的晶型及其制备方法
|
|
EP3518922B1
(en)
|
2016-09-29 |
2026-02-11 |
Receptos LLC |
Compounds and methods for treating lupus
|
|
WO2018136893A1
(en)
|
2017-01-23 |
2018-07-26 |
Naqi Logics, Llc |
Apparatus, methods, and systems for using imagined direction to define actions, functions, or execution
|
|
CN110545848A
(zh)
|
2017-02-16 |
2019-12-06 |
艾尼纳制药公司 |
用于治疗具有肠外表现的炎症性肠病的化合物和方法
|
|
WO2018151873A1
(en)
|
2017-02-16 |
2018-08-23 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
|
US10981900B2
(en)
*
|
2017-02-28 |
2021-04-20 |
Medshine Discovery Inc. |
Spiro compound and use thereof
|
|
WO2018211323A1
(en)
*
|
2017-05-17 |
2018-11-22 |
Oppilan Pharma Ltd. |
Hetercyclic compounds for the treatment of disease
|
|
US11117876B2
(en)
|
2017-08-31 |
2021-09-14 |
Receptos Llc |
Crystalline form of ozanimod hydrochloride, and processes for preparation thereof
|
|
WO2019094409A1
(en)
|
2017-11-07 |
2019-05-16 |
Teva Pharmaceuticals International Gmbh |
Salts and solid state forms of ozanimod
|
|
US12156866B2
(en)
|
2018-06-06 |
2024-12-03 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
|
EP3847158A1
(en)
|
2018-09-06 |
2021-07-14 |
Arena Pharmaceuticals, Inc. |
Compounds useful in the treatment of autoimmune and inflammatory disorders
|
|
AR116479A1
(es)
|
2018-09-25 |
2021-05-12 |
Quim Sintetica S A |
Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios
|
|
WO2020152718A1
(en)
|
2019-01-25 |
2020-07-30 |
Mylan Laboratories Limited |
Polymorphic forms 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyethyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-methylethoxy)benzonitrile
|
|
CN114008034A
(zh)
*
|
2019-04-26 |
2022-02-01 |
瑞塞普托斯公司 |
1-磷酸鞘氨醇受体调节剂
|
|
CN112062785B
(zh)
*
|
2019-06-11 |
2023-06-27 |
广东东阳光药业有限公司 |
奥扎莫德及其中间体的制备方法
|
|
WO2021026479A1
(en)
*
|
2019-08-07 |
2021-02-11 |
Stamford, Andrew |
Small molecule inhibitors of s1p2 receptor and uses thereof
|
|
EP4076448A4
(en)
|
2019-12-20 |
2024-03-27 |
Tenaya Therapeutics, Inc. |
Fluoroalkyl-oxadiazoles and uses thereof
|
|
KR20220158743A
(ko)
*
|
2020-03-27 |
2022-12-01 |
리셉토스 엘엘씨 |
스핑고신 1 포스페이트 수용체 조절제
|
|
EP4126828A1
(en)
*
|
2020-03-27 |
2023-02-08 |
Receptos Llc |
Sphingosine 1 phosphate receptor modulators
|
|
WO2021195396A1
(en)
*
|
2020-03-27 |
2021-09-30 |
Receptos Llc |
Sphingosine 1 phosphate receptor modulators
|
|
WO2021207051A1
(en)
*
|
2020-04-06 |
2021-10-14 |
Bristol-Myers Squibb Company |
Methods of treating acute respiratory disorders
|
|
US20230233532A1
(en)
*
|
2020-06-26 |
2023-07-27 |
The Penn State Research Foundation |
Sphingosine-1-phosphate receptor 1 agonist and liposomal formulations thereof
|
|
CA3191164A1
(en)
*
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
|
EP4333841A1
(en)
|
2021-05-04 |
2024-03-13 |
Tenaya Therapeutics, Inc. |
2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef
|
|
WO2023152767A1
(en)
|
2022-02-11 |
2023-08-17 |
Mylan Laboratories Limited |
Polymorphic forms of ozanimod hydrochloride
|
|
WO2024117172A1
(ja)
|
2022-11-30 |
2024-06-06 |
花王株式会社 |
痒みの予防又は改善剤
|
|
WO2024246174A1
(en)
|
2023-05-31 |
2024-12-05 |
Química Sintética, S.A. |
Amorphous and crystalline form of ozanimod hydrochloride
|
|
CN119320366B
(zh)
*
|
2023-07-17 |
2025-11-18 |
中国医学科学院药物研究所 |
取代萘甲基噁二唑-苯胺类化合物及其用途
|
|
US11905265B1
(en)
*
|
2023-10-13 |
2024-02-20 |
King Faisal University |
3,4-dimethoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2ylthio)acetoxy)benzimidamide as an antimicrobial compound
|
|
WO2025083549A1
(en)
|
2023-10-16 |
2025-04-24 |
Sun Pharma Advanced Research Company Limited |
Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders
|
|
US20250230251A1
(en)
|
2023-12-20 |
2025-07-17 |
Bristol-Myers Squibb Company |
Antibodies targeting il-18 receptor beta (il-18rb) and related methods
|